Aspen Pharmacare Holdings Limited (JSE:APN)
South Africa · Delayed Price · Currency is ZAR · Price in ZAc 16,639
-78 (-0.47%)
Nov 6, 2026, 5:03 PM SAST
Aspen Pharmacare Holdings Income Statement
Financials in millions ZAR. Fiscal year is July - June.
Millions ZAR. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 34,870 | 35,336 | 44,706 | 40,709 | 38,606 | |
Revenue Growth | -1.32% | -20.96% | 9.82% | 5.45% | 2.22% |
Cost of Revenue | 20,071 | 20,686 | 25,290 | 21,840 | 20,350 |
Gross Profit | 14,799 | 14,650 | 19,416 | 18,869 | 18,256 |
Selling, General & Admin | 8,822 | 9,378 | 10,100 | 9,394 | 8,522 |
Other Operating Expenses | 728 | 858 | 449 | 546 | 991 |
Operating Expenses | 9,550 | 10,236 | 10,549 | 9,940 | 9,516 |
Operating Income | 5,249 | 4,414 | 8,867 | 8,929 | 8,740 |
Interest Expense | -1,736 | -1,715 | -2,279 | -1,362 | -829 |
Interest & Investment Income | 334 | 332 | 1,059 | 529 | 105 |
Currency Exchange Gain (Loss) | 2 | 110 | -49 | -688 | 46 |
Other Non Operating Income (Expenses) | 219 | -145 | -15 | 254 | 138 |
EBT Excluding Unusual Items | 4,068 | 2,996 | 7,583 | 7,662 | 8,200 |
Merger & Restructuring Charges | -2,315 | -837 | -227 | -278 | -171 |
Impairment of Goodwill | -3 | - | -145 | - | -11 |
Gain (Loss) on Sale of Assets | - | - | - | - | 1,212 |
Asset Writedown | -2,548 | -4,743 | -1,522 | -1,064 | -1,194 |
Legal Settlements | - | - | - | - | -75 |
Pretax Income | -418 | -2,208 | 5,714 | 6,555 | 8,134 |
Income Tax Expense | 470 | 520 | 1,310 | 1,327 | 1,646 |
Earnings From Continuing Operations | -888 | -2,728 | 4,404 | 5,228 | 6,488 |
Earnings From Discontinued Operations | 3,535 | 1,645 | - | - | - |
Net Income to Company | 2,647 | -1,083 | 4,404 | 5,228 | 6,488 |
Net Income | 2,647 | -1,083 | 4,404 | 5,228 | 6,488 |
Net Income to Common | 2,647 | -1,083 | 4,404 | 5,228 | 6,488 |
Net Income Growth | - | - | -15.76% | -19.42% | 35.00% |
Shares Outstanding (Basic) | 444 | 444 | 444 | 444 | 453 |
Shares Outstanding (Diluted) | 444 | 444 | 444 | 444 | 453 |
Shares Change | 0.02% | -0.04% | - | -1.94% | -0.77% |
EPS (Basic) | 5.96 | -2.44 | 9.91 | 11.77 | 14.32 |
EPS (Diluted) | 5.96 | -2.44 | 9.91 | 11.77 | 14.32 |
EPS Growth | - | - | -15.76% | -17.83% | 36.04% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 4,717 | 2,583 | 3,108 | 3,290 | 3,411 |
Free Cash Flow Per Share | 10.62 | 5.82 | 7.00 | 7.41 | 7.53 |
Dividend Per Share | 2.320 | 2.110 | 3.590 | 3.420 | 3.260 |
Dividend Growth | 9.95% | -41.23% | 4.97% | 4.91% | 24.43% |
Gross Margin | 42.44% | 41.46% | 43.43% | 46.35% | 47.29% |
Operating Margin | 15.05% | 12.49% | 19.83% | 21.93% | 22.64% |
Profit Margin | 7.59% | -3.06% | 9.85% | 12.84% | 16.81% |
Free Cash Flow Margin | 13.53% | 7.31% | 6.95% | 8.08% | 8.83% |
EBITDA | 6,870 | 5,933 | 10,276 | 10,189 | 9,933 |
EBITDA Margin | 19.70% | 16.79% | 22.99% | 25.03% | 25.73% |
D&A For EBITDA | 1,621 | 1,519 | 1,409 | 1,260 | 1,193 |
EBIT | 5,249 | 4,414 | 8,867 | 8,929 | 8,740 |
EBIT Margin | 15.05% | 12.49% | 19.83% | 21.93% | 22.64% |
Effective Tax Rate | - | - | 22.93% | 20.24% | 20.24% |
Advertising Expenses | 939 | 872 | - | - | - |